| VIS ID | Virus | Ensembl ID | Gene Type | Target Gene | Oncogene | Tumor Suppressor Gene | NCBI ID | Uniprot ID |
|---|---|---|---|---|---|---|---|---|
| TVIS20051435 | HPV | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS20051277 | HPV | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS20035648 | HPV | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS20014193 | HPV | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS20051335 | HPV | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS44023476 | HTLV-1 | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS44020669 | HTLV-1 | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS44023477 | HTLV-1 | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS44014539 | HTLV-1 | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
| TVIS44041242 | HTLV-1 | ENSG00000102755.13 | protein_coding | FLT1 | Yes | No | 2321 | L7RSL3 P17948 |
Target Gene Table
▼
TCGA Plot Options
▼
Drug Information
▼
| Gene | FLT1 |
|---|---|
| DrugBank ID | DB00398 |
| Drug Name | Sorafenib |
| Target ID | BE0000029 |
| UniProt ID | P17948 |
| Regulation Type | inhibitor |
| PubMed IDs | 15466206; 16507829; 17016424; 20586710 |
| Citations | Wilhelm SM, Carter C, Tang L, Wilkie D, McNabola A, Rong H, Chen C, Zhang X, Vincent P, McHugh M, Cao Y, Shujath J, Gawlak S, Eveleigh D, Rowley B, Liu L, Adnane L, Lynch M, Auclair D, Taylor I, Gedrich R, Voznesensky A, Riedl B, Post LE, Bollag G, Trail PA: BAY 43-9006 exhibits broad spectrum oral antitumor activity and targets the RAF/MEK/ERK pathway and receptor tyrosine kinases involved in tumor progression and angiogenesis. Cancer Res. 2004 Oct 1;64(19):7099-109.@@Carlomagno F, Anaganti S, Guida T, Salvatore G, Troncone G, Wilhelm SM, Santoro M: BAY 43-9006 inhibition of oncogenic RET mutants. J Natl Cancer Inst. 2006 Mar 1;98(5):326-34.@@Wilhelm S, Carter C, Lynch M, Lowinger T, Dumas J, Smith RA, Schwartz B, Simantov R, Kelley S: Discovery and development of sorafenib: a multikinase inhibitor for treating cancer. Nat Rev Drug Discov. 2006 Oct;5(10):835-44.@@Iyer R, Fetterly G, Lugade A, Thanavala Y: Sorafenib: a clinical and pharmacologic review. Expert Opin Pharmacother. 2010 Aug;11(11):1943-55. doi: 10.1517/14656566.2010.496453. |
| Groups | Approved; Investigational |
| Direct Classification | Diarylethers |
| SMILES | CNC(=O)C1=NC=CC(OC2=CC=C(NC(=O)NC3=CC(=C(Cl)C=C3)C(F)(F)F)C=C2)=C1 |
| Pathways | Sorafenib Metabolism Pathway |
| PharmGKB | PA7000 |
| ChEMBL | CHEMBL1336 |
